Jeffrey Elliott Appointed to Quanterix’s Board of Directors
Quanterix (NASDAQ: QTRX) has appointed Jeffrey Elliott to its Board of Directors. Elliott brings 20 years of senior leadership experience in the medical diagnostics industry, including 8 years at Exact Sciences Corp. as CFO and COO. His expertise includes finance, strategy, and business development, with a track record of scaling operations and achieving high revenue growth. Elliott's appointment comes at a important time as Quanterix builds infrastructure for Alzheimer's Disease testing.
Elliott's background includes roles as a senior equity research analyst covering health care companies and a CFA® charterholder. He holds a B.S. in Business Administration from the University of Illinois and an MBA from the University of Chicago. Quanterix CEO Masoud Toloue and Board Chairman Martin Madaus expressed enthusiasm about Elliott's addition to the board, citing his valuable experience in scaling operations and financial expertise.
Quanterix (NASDAQ: QTRX) ha nominato Jeffrey Elliott nel suo Consiglio di Amministrazione. Elliott porta con sé 20 anni di esperienza nella leadership senior nel settore della diagnostica medica, inclusi 8 anni in Exact Sciences Corp. come CFO e COO. La sua esperienza comprende finanza, strategia e sviluppo commerciale, con un comprovato record nella scalabilità delle operazioni e nella crescita dei ricavi. La nomina di Elliott arriva in un momento importante mentre Quanterix costruisce infrastrutture per testare la malattia di Alzheimer.
Il background di Elliott include ruoli come analista senior di ricerca azionaria che copre aziende nel settore sanitario e il titolo di CFA®. Ha una laurea in Economia Aziendale presso l'Università dell'Illinois e un MBA presso l'Università di Chicago. Il CEO di Quanterix, Masoud Toloue, e il Presidente del Consiglio, Martin Madaus, hanno espresso entusiasmo riguardo all'aggiunta di Elliott al consiglio, citando la sua preziosa esperienza nella scalabilità delle operazioni e competenze finanziarie.
Quanterix (NASDAQ: QTRX) ha nombrado a Jeffrey Elliott en su Junta Directiva. Elliott aporta 20 años de experiencia en liderazgo superior en la industria de diagnósticos médicos, incluidos 8 años en Exact Sciences Corp. como CFO y COO. Su experiencia incluye finanzas, estrategia y desarrollo empresarial, con un historial de escalabilidad de operaciones y crecimiento significativo de ingresos. La designación de Elliott llega en un momento crucial mientras Quanterix construye infraestructuras para pruebas de la enfermedad de Alzheimer.
El historial de Elliott incluye roles como analista senior de investigación de acciones que cubre empresas de atención médica y es titular de CFA®. Tiene una licenciatura en Administración de Empresas por la Universidad de Illinois y un MBA por la Universidad de Chicago. El CEO de Quanterix, Masoud Toloue, y el presidente de la Junta, Martin Madaus, expresaron entusiasmo por la incorporación de Elliott a la junta, citando su valiosa experiencia en la escalabilidad de las operaciones y pericia financiera.
Quanterix (NASDAQ: QTRX)는 Jeffrey Elliott를 이사회에 임명했습니다. Elliott는 의료 진단 산업에서 20년의 고위 리더십 경험을 가지고 있으며, Exact Sciences Corp.에서 CFO 및 COO로 8년을 근무했습니다. 그의 전문 분야는 재무, 전략, 비즈니스 개발으로, 운영 규모 확대와 높은 수익 성장의 실적을 보유하고 있습니다. Elliott의 임명은 Quanterix가 알츠하이머 병 검사를 위한 인프라를 구축하는 중요한 시점에 이루어졌습니다.
Elliott의 경력은 의료 기업을 다루는 선임 주식 연구 분석가 및 CFA® 자격 보유자로 구성되어 있습니다. 그는 일리노이 대학교에서 경영학 학사 학위를, 시카고 대학교에서 MBA를 취득했습니다. Quanterix의 CEO인 Masoud Toloue와 이사회 의장인 Martin Madaus는 Elliott의 이사회 유입에 대해 큰 기대를 표하며, 운영 확대 및 재무 전문성에 대한 그의 귀중한 경험을 언급했습니다.
Quanterix (NASDAQ: QTRX) a nommé Jeffrey Elliott à son Conseil d'Administration. Elliott apporte avec lui 20 ans d'expérience en leadership senior dans l'industrie du diagnostic médical, dont 8 ans chez Exact Sciences Corp. en tant que CFO et COO. Son expertise inclut les finances, la stratégie et le développement commercial, avec un bilan prouvé en matière d'expansion des opérations et de croissance des revenus. La nomination d'Elliott intervient à un moment clé alors que Quanterix construit des infrastructures pour les tests de la maladie d'Alzheimer.
Le parcours d'Elliott comprend des postes en tant qu'analyste senior en recherche boursière pour des entreprises de la santé ainsi qu'une certification CFA®. Il possède une licence en administration des affaires de l'Université de l'Illinois et un MBA de l'Université de Chicago. Le PDG de Quanterix, Masoud Toloue, et le Président du Conseil, Martin Madaus, ont exprimé leur enthousiasme à l'égard de l'ajout d'Elliott au conseil, en soulignant son expérience précieuse dans l'expansion des opérations et son expertise financière.
Quanterix (NASDAQ: QTRX) hat Jeffrey Elliott in seinen Vorstand berufen. Elliott bringt 20 Jahre Erfahrung in leitenden Positionen in der medizinischen Diagnostikbranche mit, darunter 8 Jahre bei Exact Sciences Corp. als CFO und COO. Sein Fachwissen umfasst Finanzen, Strategie und Geschäftsentwicklung und er hat eine Erfolgsbilanz in der Skalierung von Operationen und dem Erreichen eines hohen Umsatzwachstums. Elliott's Berufung kommt zu einem wichtigen Zeitpunkt, da Quanterix Infrastruktur für Tests auf Alzheimer aufbaut.
Elliotts Hintergrund umfasst Positionen als leitender Aktienforschungsanalyst mit Fokus auf Gesundheitsunternehmen sowie das CFA®-Zertifikat. Er hat einen B.S. in Betriebswirtschaftslehre von der Universität Illinois und einen MBA von der Universität Chicago. Der CEO von Quanterix, Masoud Toloue, und der Vorsitzende des Vorstands, Martin Madaus, äußerten sich begeistert über Elliotts Aufnahme in den Vorstand und hoben seine wertvolle Erfahrung bei der Skalierung von Operationen und seine finanzielle Expertise hervor.
- Appointment of Jeffrey Elliott with 20 years of senior leadership experience in medical diagnostics
- Elliott's track record of scaling operations and achieving high revenue growth at Exact Sciences
- Elliott's expertise in finance, strategy, and business development
- Timing of appointment aligns with Quanterix's focus on building Alzheimer's Disease testing infrastructure
- None.
Mr. Elliott brings two decades of senior leadership experience in the medical diagnostics industry, including 8 years at Exact Sciences Corp., where he served as chief financial officer from November 2016 to May 2024 and chief operating officer from April 2021 to May 2023. While at Exact Sciences, he was responsible for finance, strategy and business development, helping to effectively scale the business, achieving high revenue growth during his tenure, and overseeing numerous acquisitions and venture investments.
Prior to joining Exact Sciences, Mr. Elliott was a senior equity research analyst at Robert W. Baird & Co. where he covered health care companies, including companies in the diagnostics and life science tools industry. He brings to Quanterix a breadth of business strategy experience within the life sciences industry.
Mr. Elliott earned a Bachelor of Science in business administration from the University of
“We’re pleased to welcome Jeff to our board of directors at an exciting time for the company. As Quanterix actively builds the infrastructure for Alzheimer’s Disease testing to ensure access to early diagnosis, Jeff's experience in scaling Exact Sciences’ operations and financial experience will be invaluable,” said Masoud Toloue, CEO of Quanterix.
“Jeff is a wonderful addition to our Board, and we look forward to leveraging his expertise in the industry as Quanterix continues to grow,” said Martin Madaus, Chairman of the Board.
“It is a pivotal time in life sciences and diagnostics, and I’m thrilled to join the Quanterix board amid great innovation and opportunity,” said Mr. Elliott. “The mission to scale Quanterix’s Simoa technology is bold and ambitious, and I am excited to apply my experience to help the company achieve this goal and support continued innovation.”
To learn more about Quanterix’s Simoa® technology, visit: https://www.quanterix.com/simoa-technology/.
About Quanterix
From discovery to diagnostics, Quanterix’s ultra-sensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company’s Simoa® technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Level of Quantification (LoQ). Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 2,900 peer-reviewed journals. Find additional information about the
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix’s actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix’s filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20240819478224/en/
Quanterix Media:
Maya Nimnicht, PAN Communications
(510) 334-6273
pan.quanterix@pancomm.com
Investor Relations:
Quanterix
Francis Pruell
(508) 789-1725
ir@quanterix.com
Source: Quanterix Corporation
FAQ
Who is the new Board of Directors member for Quanterix (QTRX)?
What is Quanterix (QTRX) focusing on in terms of product development?
What is Jeffrey Elliott's background before joining Quanterix's (QTRX) board?
How does Quanterix (QTRX) expect to benefit from Jeffrey Elliott's appointment?
